Harvey Investment Co. LLC reduced its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 1.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 217,132 shares of the medical research company's stock after selling 2,150 shares during the quarter. Agilent Technologies makes up approximately 3.4% of Harvey Investment Co. LLC's holdings, making the stock its 9th biggest position. Harvey Investment Co. LLC owned approximately 0.08% of Agilent Technologies worth $29,170,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Livelsberger Financial Advisory acquired a new position in Agilent Technologies during the third quarter worth $28,000. CKW Financial Group boosted its holdings in shares of Agilent Technologies by 114.9% during the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company's stock worth $25,000 after buying an additional 100 shares during the period. Global X Japan Co. Ltd. grew its stake in Agilent Technologies by 161.1% in the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company's stock valued at $25,000 after buying an additional 116 shares during the last quarter. Ashton Thomas Securities LLC acquired a new stake in Agilent Technologies during the third quarter worth approximately $31,000. Finally, Fortitude Family Office LLC boosted its holdings in shares of Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company's stock worth $35,000 after acquiring an additional 95 shares during the period.
Wall Street Analyst Weigh In
A has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. decreased their price target on Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 26th. StockNews.com upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research report on Tuesday, December 24th. Sanford C. Bernstein lowered their price objective on shares of Agilent Technologies from $140.00 to $135.00 and set a "market perform" rating for the company in a research report on Tuesday, November 26th. Bank of America reduced their target price on Agilent Technologies from $153.00 to $150.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. Finally, Barclays raised Agilent Technologies from an "underweight" rating to an "equal weight" rating and boosted their price target for the stock from $135.00 to $145.00 in a report on Monday. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $144.38.
Check Out Our Latest Report on A
Agilent Technologies Stock Down 1.2 %
Shares of A stock traded down $1.66 on Tuesday, reaching $142.03. 597,588 shares of the company were exchanged, compared to its average volume of 1,649,353. The company has a 50-day moving average of $141.67 and a 200-day moving average of $139.43. The company has a market cap of $40.52 billion, a price-to-earnings ratio of 32.10, a PEG ratio of 4.00 and a beta of 1.07. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58. Agilent Technologies, Inc. has a one year low of $124.16 and a one year high of $155.35.
Agilent Technologies (NYSE:A - Get Free Report) last posted its earnings results on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.41 by $0.05. The company had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The firm's revenue for the quarter was up .8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.38 earnings per share. Analysts anticipate that Agilent Technologies, Inc. will post 5.56 earnings per share for the current year.
Agilent Technologies Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st were paid a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date of this dividend was Tuesday, December 31st. This is an increase from Agilent Technologies's previous quarterly dividend of $0.24. Agilent Technologies's dividend payout ratio is 22.40%.
Insider Transactions at Agilent Technologies
In other news, CEO Padraig Mcdonnell sold 1,911 shares of the company's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the sale, the chief executive officer now directly owns 39,652 shares in the company, valued at $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link.
Agilent Technologies Company Profile
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Featured Stories
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
